Three injectable medications dominate Nigeria's GLP-1 market: Ozempic, Wegovy, and Mounjaro. All three produce meaningful weight loss, but they work through different mechanisms, come at different price points, and suit different patient profiles. This guide cuts through the marketing and gives you a clear, evidence-based comparison so you can have a more informed conversation with your pharmacist or doctor.
The Quick Answer
If you are primarily focused on maximising weight loss and can afford the higher cost, Mounjaro (tirzepatide) produces the greatest average weight reduction in clinical trials — approximately 20–22% of body weight at the highest dose. If you want a well-studied, proven medication at a lower price entry point, Ozempic is a strong choice. Wegovy is the same molecule as Ozempic but at a higher approved dose, specifically licensed for weight management.
Understanding the Mechanisms
Ozempic (Semaglutide)
Ozempic works by activating the GLP-1 receptor — a gut hormone pathway that signals satiety, slows gastric emptying, and modestly reduces blood sugar. Originally approved for type 2 diabetes, it is widely used off-label (and in some markets on-label) for weight loss. Its long half-life of approximately 7 days makes it ideal for once-weekly dosing.
Wegovy (Semaglutide 2.4 mg)
Wegovy is identical to Ozempic in its active ingredient — semaglutide — but is delivered at a higher maximum dose of 2.4 mg weekly (versus 1–2 mg for Ozempic). This higher dose produces greater average weight loss. Wegovy is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Mounjaro (Tirzepatide) Highest Weight Loss
Mounjaro's key differentiator is its dual-action mechanism. It simultaneously activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP amplifies the GLP-1 signal in a synergistic way that produces greater fat loss than either pathway alone. The SURMOUNT clinical trials showed average body weight reductions of 20–22% at the 15 mg dose — a result previously unseen outside bariatric surgery.
Head-to-Head Comparison Table
| Feature | Ozempic | Wegovy | Mounjaro |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP agonist |
| Max weekly dose | 2 mg | 2.4 mg | 15 mg |
| Avg weight loss | ~9% | ~15% | ~21% |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| Primary approval | Type 2 diabetes | Weight management | Type 2 diabetes / obesity |
| Blood sugar control | Good | Good | Excellent |
| Nigeria availability | Widely available | Available | Available |
| Relative cost in Nigeria | ₦₦ | ₦₦₦ | ₦₦₦ |
Side Effect Profiles: What's Different?
Because all three drugs activate the GLP-1 pathway, their side effect profiles overlap significantly. The most common effects — nausea, constipation, diarrhoea — occur with all three. The intensity tends to be dose-dependent.
Mounjaro's additional GIP action does not add new side effect categories, but some clinical data suggest it may cause slightly more nausea at the 5 mg+ range compared to equivalent semaglutide doses. However, the difference is modest and most patients tolerate all three well when the dose escalation schedule is followed properly.
Important: None of these medications should be used without pharmacist or physician oversight. The contraindications (personal or family history of medullary thyroid cancer, MEN 2, pancreatitis) apply to all three.
Which Drug Should You Choose?
Choose Ozempic if:
- You have type 2 diabetes alongside your weight management goal
- You want the most established long-term safety record
- Budget is a priority and you are comfortable with ~5–10% weight loss
- You are new to GLP-1 therapy and want to start with the most widely-used option
Choose Wegovy if:
- Your primary goal is weight loss (not diabetes management)
- You have already tried Ozempic and want a higher semaglutide dose
- You want a medication specifically approved for chronic weight management
Choose Mounjaro if:
- You want the highest potential weight loss outcome from a single injection
- You have type 2 diabetes and want the best blood sugar control alongside weight loss
- Previous GLP-1 therapy (Ozempic/Wegovy) gave limited results
- You are targeting 15–20%+ body weight reduction
A Note on Cost in Nigeria
All three medications are expensive. Ozempic tends to be slightly more affordable in the Nigerian market because it has been available longer and supply chains are more established. Mounjaro and Wegovy carry a premium. Always verify that you are paying for a genuine, cold-chain-verified product — the price difference between a real pen and a counterfeit is sometimes negligible, which is exactly why fakes proliferate.
Our pharmacist recommendation: For most patients starting GLP-1 therapy in Nigeria, we recommend beginning with Ozempic at the standard dose escalation. If you hit a plateau or need more aggressive results, transitioning to Mounjaro is a well-supported clinical step. Always make this decision with your dispensing pharmacist or physician.
Not Sure Which to Start With?
Our licensed pharmacists can help you decide based on your goals, health history, and budget — all via a free WhatsApp consultation.
Chat with Our Pharmacist